Status:
COMPLETED
Pharmacogenetic Study in Hepatocellular Carcinoma Patients.
Lead Sponsor:
Rehab Werida
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
20-75 years
Brief Summary
evaluate the prognostic value of genetic polymorphisms in HCC Egyptian patients undergoing TACE using lipiodol and doxorubicin.
Detailed Description
Research Objectives This study aims to determine the predictive effect of ANG-2 and IL28B genetic polymorphisms in safety and efficacy of doxorubicin and lipiodol used for the treatment of Egyptian HC...
Eligibility Criteria
Inclusion
- Eligible patients should fulfill the following criteria:
- A diagnosed HCC patient.
- Age ≥20 years.
- Patients with adequate organ function.
- HCC not eligible for curative measures (radiofrequency, microwave and surgery).
Exclusion
- Patient will be excluded for any of the following:
- Patients refused to sign the written consent.
- Age \> 75 years.
- The presence of major portal vein thrombosis.
- Extrahepatic metastases.
- Hepatic encephalopathy.
- Current infection.
- Gastrointestinal bleeding within a month.
- Uncontrolled ascites.
- Serum bilirubin \> 3.0 mg/dl, serum albumin \< 2.8 g/dl, serum creatinine concentration \> 1.5 mg/dl, white blood cell counts \< 3,000/mm3 and platelet counts \< 30,000/mm3.
- Patients with other types of malignancy, advanced organ failure, and advanced medical co-morbidity.
- Pregnant females.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2023
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT05291338
Start Date
January 1 2022
End Date
April 1 2023
Last Update
July 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University hepatoma group, EL Demerdash Hospital, Cairo, Egypt.
Cairo, Egypt